Remove Innovations Remove Office Remove Safety
article thumbnail

Meet the First-ever Recipients of The Lupus Research Alliance’s Translational Bridge Award

The Dermatology Digest

. “The new Translational Bridge Award addresses a critical gap in lupus research, enabling scientists to bring their most promising ideas closer to people living with lupus,” says Teodora Staeva, PhD, LRA Vice President and Chief Scientific Officer, in a news release.

article thumbnail

HS Pipeline Watch: MoonLake Immunotherapeutics’ Sonelokimab Advances to Phase 3

The Dermatology Digest

The unique characteristics and mode of action of MoonLake’s Nanobody, sonelokimab to effectively inhibit IL-17F in addition to IL-17A in deep tissue inflammation has to date shown promising outcomes, highlighting the importance of this Phase 3 program, and placing HS at the forefront of dermatological innovation.”

Safety 68
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

HS Pipeline Watch: MoonLake Immunotherapeutics’ Sonelokimab Heads to Phase 3

The Dermatology Digest

“The favorable response from both the FDA and EMA aligns with the strengths we have consistently highlighted in our trial programs and outlines a clear regulatory path for sonelokimab in hidradenitis suppurativa” says Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, in a news release.“

Office 74
article thumbnail

Happy Italian American Heritage Month!

New Age Spa Institute

link] Peter Thomas Roth Italian American Skincare entrepreneur and founder of Peter Thomas Roth skincare brand, known for innovative solutions. It integrates the industry’s most potent laser-emitting diode with an innovative double cooling system that utilizes copper and gold macrochannels.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. The BIG story is Janus kinase ( JAK ) inhibitors,” Dr. Martin says.

article thumbnail

Red Light Therapy: A Revolutionary Approach to Skin and Health

US Dermatologt Partners

Red light therapy is considered one of the newest and most innovative skin rejuvenation procedures available. Safety and Side Effects This procedure is considered safe. Dr. Charles says, “Any procedure that is still considered emerging or in development will have associated risks because regulations don’t exist yet to ensure safety.

Therapy 41
article thumbnail

Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”

The Dermatology Digest

The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. Chief Executive Officer of Apogee, in a news release. . Chief Executive Officer of Apogee, in a news release. “We